Stocktoria
CORCEPT THERAPEUTICS INC CORT
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2004-04-15
CORCEPT THERAPEUTICS INC financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $761.4M | $675.0M | $482.4M | $401.9M | $366.0M |
| R&D expense | $254.9M | $246.9M | $184.4M | $131.0M | $113.9M |
| SG&A expense | $448.7M | $280.3M | $184.3M | $152.8M | $122.4M |
| Operating income | $44.8M | $137.0M | $107.3M | $112.6M | $124.5M |
| Income tax | -$33.2M | $20.3M | $18.4M | $14.8M | $12.5M |
| Net income | $99.7M | $141.2M | $106.1M | $101.4M | $112.5M |
| EPS (diluted) | $0.82 | $1.23 | $0.94 | $0.87 | $0.89 |
| Operating cash flow | $142.0M | $198.3M | $126.7M | $120.3M | $167.9M |
| Free cash flow | $141.8M | $196.1M | $126.5M | $119.9M | $167.4M |
| Cash & equivalents | $120.5M | $127.7M | $135.6M | $66.3M | $77.6M |
| Inventory | $12.9M | $12.4M | $7.7M | $6.1M | $5.0M |
| Total assets | $836.7M | $840.6M | $621.5M | $583.4M | $423.8M |
| Total liabilities | $188.8M | $161.0M | $114.8M | $81.6M | $48.0M |
| Shareholders' equity | $647.8M | $679.6M | $506.7M | $501.8M | $375.8M |
Source: SEC EDGAR filings · CIK 0001088856 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.